Redeye has updated its estimates for Carasent following the Q1 2024 report, which was more or less in line with our estimates, and the revised financial targets, which were slightly more upbeat than our old forecasts, not least on how fast Carasent can scale its EBITDA-Capex margin. Carasent is starting to pick up steam, after a year of internal improvements, which now are starting to shine through in the reported numbers. We also comment on EG’s contemplated bid.